IRD (ixazomib, lenalidomide, and dexamethasone) consolidation therapy after autologous peripheral hematopoietic stem cell transplantation for elderly multiple myeloma patients.
Not Applicable
Recruiting
- Conditions
- multiple myaloma
- Registration Number
- JPRN-UMIN000039016
- Lead Sponsor
- Tokyo-Kita Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 28
Inclusion Criteria
Not provided
Exclusion Criteria
1) Peripheral neuropathy grade > 2 2) Uncontrolled diabetes. 3) Uncontrolled hypertension, arrhythmia, or heart failure. 4) Uncontrolled infectious diseases. 5) Uncontrolled psychiatric disorders. 6) Pregnant or lactating patients. 7) Allergic to ixazomib or lenalidomide. 8) Inability to comply with RevMmate. 9) Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method